MX2023008219A - Derivados de pirazolo[3,4-d]pirimidin-6-il-sulfonamida para la inhibición de la serina/treonina proteina cinasa (sgk-1). - Google Patents

Derivados de pirazolo[3,4-d]pirimidin-6-il-sulfonamida para la inhibición de la serina/treonina proteina cinasa (sgk-1).

Info

Publication number
MX2023008219A
MX2023008219A MX2023008219A MX2023008219A MX2023008219A MX 2023008219 A MX2023008219 A MX 2023008219A MX 2023008219 A MX2023008219 A MX 2023008219A MX 2023008219 A MX2023008219 A MX 2023008219A MX 2023008219 A MX2023008219 A MX 2023008219A
Authority
MX
Mexico
Prior art keywords
sgk
pyrazolo
pyrimidin
inhibition
sulfonamide derivatives
Prior art date
Application number
MX2023008219A
Other languages
English (en)
Spanish (es)
Inventor
Marc Vidal
Maroua Khalifa
Martin Maguire
Original Assignee
Thryv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thryv Therapeutics Inc filed Critical Thryv Therapeutics Inc
Publication of MX2023008219A publication Critical patent/MX2023008219A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023008219A 2021-01-13 2022-01-12 Derivados de pirazolo[3,4-d]pirimidin-6-il-sulfonamida para la inhibición de la serina/treonina proteina cinasa (sgk-1). MX2023008219A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163136782P 2021-01-13 2021-01-13
US202163262040P 2021-10-04 2021-10-04
PCT/CA2022/050038 WO2022150911A1 (en) 2021-01-13 2022-01-12 Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1

Publications (1)

Publication Number Publication Date
MX2023008219A true MX2023008219A (es) 2023-08-24

Family

ID=82446316

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008219A MX2023008219A (es) 2021-01-13 2022-01-12 Derivados de pirazolo[3,4-d]pirimidin-6-il-sulfonamida para la inhibición de la serina/treonina proteina cinasa (sgk-1).

Country Status (8)

Country Link
US (1) US20240309005A1 (enExample)
EP (1) EP4277905A4 (enExample)
JP (1) JP2024502178A (enExample)
KR (1) KR20230136622A (enExample)
CN (1) CN121517419A (enExample)
AU (1) AU2022208639A1 (enExample)
MX (1) MX2023008219A (enExample)
WO (1) WO2022150911A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525475A (ja) * 2022-07-12 2025-08-05 スリブ セラピューティクス インコーポレイテッド Ｎ－［４－（４－［［２－（ジメチルアミノ）エチル］アミノ］－３－メチル－１Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－６－イル）－２－フルオロフェニル］－２，５－ジフルオロベンゼンスルホンアミドの塩及びそれらの結晶形態
WO2024015055A1 (en) * 2022-07-13 2024-01-18 Thryv Therapeutics Inc. Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer
KR102912267B1 (ko) * 2023-04-20 2026-01-15 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
WO2025072438A1 (en) * 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Piperidine substituted pyrazolopyrimidine derivatives as inhibitors of sgk1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5827849B2 (ja) * 2011-09-20 2015-12-02 サノフイ Ｎ−［４−（１Ｈ−ピラゾロ［３，４−ｂ］ピラジン−６−イル）−フェニル］−スルホンアミド及び薬剤としてのその使用
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
WO2015048531A1 (en) * 2013-09-26 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Inhibition of sgk1 in the treatment of heart conditions
AU2017373758B2 (en) * 2016-12-07 2021-12-16 Orimos Therapeutics Co., Ltd. Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof

Also Published As

Publication number Publication date
WO2022150911A8 (en) 2022-09-09
CA3172186A1 (en) 2022-07-21
EP4277905A1 (en) 2023-11-22
EP4277905A4 (en) 2025-01-01
CN121517419A (zh) 2026-02-13
WO2022150911A1 (en) 2022-07-21
KR20230136622A (ko) 2023-09-26
US20240309005A1 (en) 2024-09-19
JP2024502178A (ja) 2024-01-17
AU2022208639A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
MX2023008219A (es) Derivados de pirazolo[3,4-d]pirimidin-6-il-sulfonamida para la inhibición de la serina/treonina proteina cinasa (sgk-1).
Uhrin et al. Vascular smooth muscle cell proliferation as a therapeutic target. Part 2: Natural products inhibiting proliferation
PH12021553238A1 (en) Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors
MX2023010806A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
US9422297B2 (en) Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
NZ766835A (en) Pharmaceutical compounds
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
SA523440916B1 (ar) Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات
CR20210626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
CR20200620A (es) Compuestos de purinona y su uso en el tratamiento del cáncer campo
JP2008538546A (ja) 低酸素選択的タンパク質キナーゼ阻害剤としての複素環ｎ−オキシド
ES2176251T3 (es) Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf).
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
AR020321A1 (es) Derivados del acido antranilico, procedimiento para prepararlos, composiciones farmaceuticas formuladas con dichos derivados; uso de dichos derivados parala fabricacion de dichas composiciones y metodo para el tratamiento de enfermedades aplicando los derivados mencionados.
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
PH12021552513A1 (en) Pyrrole compounds
MX2024008868A (es) Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
CN101484443B (zh) 放射线治疗增强剂
CN101027053A (zh) Hsp90抑制剂
NZ761680A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
WO2024158996A3 (en) Exatecan immunoconjugates
CA3124938A1 (en) Novel compound and pharmaceutical composition comprising same for enhancing anticancer activity
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.